Leukocytes decline > 2500/µl during Peginterferon Alfa-2B (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR rates in difficult-to-treat patients with HCV Genotype 1 (G1) i…
G Teuber, S Mauss, D Hüppe, E Zehnter, MP Manns, T Dahhan, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2013 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background and aims: Leukocyte decline during antiviral treatment of chronic HCV infection may reflect pharmacodynamic effects of pegylated interferons. We therefore investigated the possible association between leukocyte decline and SVR in difficult-to-treat patients (pts) undergoing Peg2b/RBV therapy for HCV G1 infection in real-life. Methods: Data from the German Peg2b/RBV observational study were retrospectively analyzed. This real-life cohort study assessed the safety and efficacy of treatment of G1 infection with Peg2b 1.5 µg/kg/week + weight-based RBV (800 – 1200 mg/day) for up to 48 weeks at 285 sites. S…
